Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

Ítems similars

• Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation
  per: Lee, Sang Hoon, et al.
  Publicat: (2020)
• Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
  per: Kim, Eun Young, et al.
  Publicat: (2019)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  per: Chen, Zhi-Yong, et al.
  Publicat: (2012)
• EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
  per: Yang, Jiyoul, et al.
  Publicat: (2018)
• Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
  per: Brindel, Aurélien, et al.
  Publicat: (2020)